Participated · Seed · Jun 2026

Clario’s platform connects into enterprise file and content systems such as Google Drive, SharePoint, OneDrive, Box, and Confluence to scan metadata and surface redundant, obsolete, and trivial files. When files are flagged, Clario triggers intelligent workflows via Slack and Teams that prompt customers to keep, archive, or delete items, and the company reports it only gets paid when customers make one of those decisions. Over time the product learns from customer decisions to build an autonomous system that routinely cleans and maintains unstructured data. The company says it has engaged with hundreds of enterprises and is already working with several marquee organizations; early customer analysis reportedly uncovered terabytes of garbage data across multiple environments. Clario’s founders bring enterprise operating and engineering backgrounds including a five-time CIO and an engineering leader with experience at Oracle, NetApp, Nutanix, and VMware. The company is based in Menlo Park, California.

Led · Equity · Jan 2026

iSono Health is a commercial-stage medical technology company focused on transforming women’s breast imaging with ATUSA™, an FDA-cleared, portable and hands-free 3D ultrasound platform. The system captures full-breast volumes in about two minutes per breast—roughly ten times faster than manual handheld ultrasound—and delivers consistent images independent of the operator’s skill. By pairing its wearable hardware with cloud-based intelligence, the company offers an "Ultrasound-as-a-Service" model that lowers upfront costs for clinics and generates recurring revenue. iSono is advancing an AI "sentient partner" roadmap to provide real-time diagnostic support and is running the 800-patient, NIH-funded AUDIBLE Study to validate its algorithms against mammography and MRI. The company has secured multiple paying clinics through a Pioneering Partner Program and earned industry recognition such as HLTH 2025 Rising Star (Diagnostics) and WISH 2024 Global Awards. Financially, iSono has raised $14.7 million across venture rounds and non-dilutive grants, including a recent $3 million Seed Preferred round and $3.7 million from NIH, NSF and NCI. These funds position the firm to scale global deployments while continuing clinical validation.

Participated · Seed · Oct 2025

Developer of a consumer financial platform designed to improve credit scores and reduce interest rates for American consumers. The company's app offers a rewards-based credit builder card, installment loans, cash flow-based underwriting, automatic payments, and detailed financial analysis, enabling users to increase on-time payments and lengthen their overall credit history.

Participated · Seed · Feb 2024

Competera builds an intelligent price optimization platform for retailers using a neural network trained on proprietary and industry data. The Competera Pricing Platform enables retailers to set and maintain optimal prices across the entire pricing life cycle, and the company offers Competera X, a self-service version for sellers on marketplaces like Amazon, Etsy, and Shopify. The company has more than 50 customers across 18 countries, including the US, UK, Germany, France and Italy. Co-founded by Oleksandr Halkin and Oleksandr Sazonov and based in Santa Monica, CA, Competera says its mission is to free retailers from pricing routines. In January 2024 Competera secured $3.0M in seed funding. The company will use the funds to scale services supporting multinational retailers and expand further in the US retail sector.

Participated · Seed · Jan 2024

NEXT Life Sciences is developing Plan A™, a device-based, non-hormonal male contraceptive that places a biocompatible Vasalgel® hydrogel in the vas deferens to block sperm flow. Plan A™ is designed to provide up to 10 years of pregnancy prevention while remaining reversible via a dissolving procedure. NEXT acquired the worldwide license to Vasalgel® in 2022 and has since optimized the technology toward clinical development. The company plans to start clinical trials for Plan A™ in 2024 and intends to pursue FDA marketing authorization following trials. NEXT’s leadership includes experienced executives and clinicians from medical device and contraceptive fields. Financially, the company recently received a $400K grant from the Male Contraceptive Initiative and completed a prior fundraising round led by Bolt.com founder Ryan Breslow and The Family with participation from Transform VC and angel and early-stage venture investors. NEXT Life Sciences, based in Los Angeles, is a medical device company developing Plan A, a non-hormonal, long-acting, reversible on-demand male contraceptive. Plan A's design utilizes a hydrogel (Vasalgel®) that acts as a flexible filter to block sperm flow in the vas deferens. NEXT acquired the exclusive worldwide license for Vasalgel® in 2022 and aims to advance the technology through FDA authorization and to market. The company plans to start clinical trials for Plan A in 2024, followed by submission to the FDA. NEXT announced an oversubscribed $2.5M funding round led by The Family, bringing total seed funding to date to $4M. Ryan Breslow has joined as a strategic advisor, and NEXT says its executive team has prior leadership experience in medical device and contraceptive commercialization. NEXT Life Sciences is developing Plan A™, a reversible male contraceptive that uses Vasalgel®, a proprietary hydrogel the company acquired. The Plan A procedure is similar to a no‑scalpel vasectomy but inserts a hydrogel filter to block sperm flow rather than cutting the vas deferens. Preclinical studies showed rapid restoration of sperm flow after Vasalgel® was dissolved and flushed from the vas deferens. The company raised $1.55M in seed funding to support development and commercialization of Plan A. NEXT is led by CEO L.R. Fox and has assembled a Medical Advisory Board to guide contraceptive development, including Dr. Charles Carignan. The company aims to initiate clinical trials by the end of 2023.